Price
Target price
€12.50
€12.50
-5.300%
-0.7
-5.300%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Osaka Titanium Technologies Stock
Osaka Titanium Technologies took a tumble today and lost -€0.700 (-5.300%).
So far the community has only identified positive things for Osaka Titanium Technologies stock. The most positive votes were given for criterium "Brand".
Pros and Cons of Osaka Titanium Technologies in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Osaka Titanium Technologies vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Osaka Titanium Technologies | -5.300% | 0.763% | -7.692% | - | - | - | - |
| Furukawa Co. Ltd. | -4.420% | 10.784% | 0.893% | 73.846% | 8.654% | 151.111% | 145.652% |
| Pacific Metals Co Ltd | -1.630% | 4.310% | -5.469% | 17.476% | 0.000% | 13.084% | -11.029% |
| Mitsui Mining and Smelting Corp Ltd. | 0.280% | 24.903% | 40.000% | 880.952% | 201.990% | 1286.538% | 1153.913% |
News
Is Green Thumb Becoming the "Procter & Gamble of Cannabis"?
Procter & Gamble (NYSE: PG) is known for its steady earnings growth and family of well-known consumer brands. While it's hard to compare a nearly 190-year-old consumer goods company to one in the
Gemini Space Station Q1 Earnings Call Highlights
Gemini Space Station (NASDAQ:GEMI) reported higher first-quarter revenue as the crypto platform said it is moving to diversify beyond digital asset trading through credit cards, over-the-counter
Prestige Consumer Healthcare Q4 Earnings Call Highlights
Prestige Consumer Healthcare (NYSE:PBH) reported a weaker-than-expected fourth quarter as supply constraints in eye care and shipping disruptions tied to conflict in the Middle East weighed on